Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.

Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of imatinib drug are expected to drive the imatinib drug market. According to the National Cancer Institute, in June 2017, it was estimated that there will be around 62,130 and 24,500 people with new cases and death due to leukemia, respectively, in the U.S.

Download Request Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/2648

Furthermore, rise in healthcare expenditure and increase in awareness of cancer by government and private organizations are anticipated to boost the market growth. In addition, R&D activities related to imatinib are anticipated to present new opportunities during the forecast period. However, high cost of imatinib; adverse effects; presence of substitutes, such as sprycel, tarceva, and tasigna; and stringent government regulations may hinder the market growth.

The imatinib drug market is segmented on the basis of application, drug formulation, and geography. Based on application, it is divided into aggressive systemic mastocytosis (ASM), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST), hyper-eosinophilic syndrome (HES), myelodysplastic syndrome (MDS), myeloproliferative diseases (MPD), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Based on the drug formulation, the market is bifurcated into tablets and capsules. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits:

The study provides an in-depth analysis of the global imatinib drug market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report presents a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.
Send Enquiry Us @ https://www.alliedmarketresearch.com/purchase-enquiry/2648

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.